Literature DB >> 11005509

Vascular endothelial growth factor and osteopontin in tumor biology.

N Shijubo1, T Uede, S Kon, M Nagata, S Abe.   

Abstract

Tumor growth and metastasis are angiogenesis-dependent and tumor angiogenesis is a result of complex interplay of positive and negative regulators. Vascular endothelial growth factor (VEGF) occupies a particular place among the positive regulators of angiogenesis due to its potency and specificity for endothelial cells. VEGF upregulates several molecules such as growth factors, adhesion molecules, proteases, and protease receptors and it actually induces microvascular hyperpermeability, resulting in activation of thrombin from prothrombin. Osteopontin (OPN) is a secreted arginine-glycine-asparic acid (RGD)-containing phosphoprotein and it contains a predicted thrombin cleavage site. OPN binds to several integrins and CD44 variants. OPN has diverse functions such as cell adhesion, chemoattraction, and immunomodulation, and it induces endothelial cell migration and upregulates endothelial cell migration induced by VEGF. OPN expression is upregulated in human carcinomas. This review documents the functional roles of VEGF and OPN in angiogenesis and their clinical significance in tumor biology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005509

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  29 in total

1.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

2.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.

Authors:  Hui Zhang; Qing-Hai Ye; Ning Ren; Lei Zhao; Yan-Fang Wang; Xin Wu; Hui-Chuan Sun; Lu Wang; Bo-Heng Zhang; Yin-Kun Liu; Zhao-You Tang; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

4.  Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Authors:  Kuan-Yin Tseng; Min-Huey Chung; Huey-Kang Sytwu; Horng-Mo Lee; Kuan-Yu Chen; Chen Chang; Chih-Kung Lin; Che-Hung Yen; Jia-Hong Chen; Gu-Jiun Lin; Hsin-I Ma; Yi-Shian Yeh; Da-Tong Ju; Ming-Ying Liu; Dueng-Yuan Hueng
Journal:  J Neurooncol       Date:  2010-04-29       Impact factor: 4.130

Review 5.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

6.  The downregulation of OPN inhibits proliferation and migration and regulate activation of Erk1/2 in ECA-109 cells.

Authors:  Song-Tao Xu; Fa-Zhang Zou; Li-Na Cai; Wan-Ling Xu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

7.  Effect of stretching force on the cells of epithelial rests of malassez in vitro.

Authors:  Teruyoshi Koshihara; Kenichi Matsuzaka; Toru Sato; Takashi Inoue
Journal:  Int J Dent       Date:  2010-04-12

8.  Expression of phosphorylated-STAT3 and osteopontin and their correlation in melanoma.

Authors:  Yan Wu; Ping Jiang; Yun Lin; Siyuan Chen; Nengxing Lin; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

9.  Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer.

Authors:  Zhiyong Mi; Hongtao Guo; Paul C Kuo
Journal:  BMC Res Notes       Date:  2009-07-01

10.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Authors:  Anita L Bane; Dushanthi Pinnaduwage; Sarah Colby; Michael Reedijk; Sean E Egan; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.